Navigation Links
High-dose anticlotting drug cuts heart attack, death risk in half

Pretreatment with double-dose anticlotting medication just before percutaneous coronary intervention (PCI) cuts the combined risk of heart attack and cardiac death by half, according to a study reported at the 30th Annual Scientific Sessions of the Society for Cardiovascular Angiography and Interventions (SCAI), May 9?2, 2007, in Orlando, FL.

Researchers found that giving patients at least 600 mg of clopidogrel before stenting, rather than the standard 300-mg dose, halved the risk of major complications associated with blood clotting, or thrombosis. In addition, the higher dose did not increase the risk of serious bleeding.

"This research has important clinical and cost implications," said Giuseppe G. Biondi-Zoccai, M.D., an assistant professor of cardiology at the University of Turin, in Turin, Italy. "The goal of antithrombotic management for PCI is to maximize protection from thrombotic complications during and shortly after PCI, while minimizing bleeding and costs."

Clopidogrel interferes with the action of platelet cells, which stimulate the formation of blood clots. Interventional cardiologists give patients a loading dose of this medication before PCI to protect against blood clotting. After the procedure, most patients take a lower daily dose (75 mg) for up to a year, depending on the type of stent used to prop open the clogged coronary artery.

To evaluate the effect of the clopidogrel loading dose, researchers from University of Turin and Virginia Commonwealth University, in Richmond, performed a meta-analysis of data from 10 studies involving more than 1,500 patients. Roughly half of the patients were pretreated with 300 mg of clopidogrel and the other half with 600 mg. A few received either 450 mg or 900 mg of clopidogrel.

Overall, pretreatment with high-dose clopidogrel (600 mg or more) was associated with a 50 percent reduction in the risk of cardiac death or nonfatal heart attack, both during the initial hospitalization and within 30 days of the PCI procedure, a finding that was highly statistically significant (p=0.009). There was no statistically significant increase in major or minor bleeding (p=0.55 and p=0.98, respectively). Findings remained the same when the analysis was restricted to 7 randomized controlled trials only. Further analysis showed that the higher the underlying risk of complications related to blood clotting, the greater the benefit from high-dose clopidogrel.

The study will be presented at the Orlando SCAI meeting by Antonio Abbate, M.D., an assistant professor of medicine, Virginia Commonwealth University, Pauley Heart Center, Richmond, VA.


'"/>

Source:Society for Cardiovascular Angiography and Interventions


Related biology news :

1. High-dose flu vaccines appear to safely boost immunity in elderly
2. UCSD team discovers specialized, rare heart stem cells in newborns
3. Single stem cells from bone heal a broken heart
4. Python a hearty eater
5. Columbia study shows widely used artery clearing device does not help patients during heart attack
6. Researchers reveal secret of key protein in brain and heart function
7. Stem cell therapy successfully treats heart attack in animals
8. New defibrillator signals doctor of patients irregular heartbeat or device malfunction
9. Survival of heart patients on beta-blockers varies greatly with genetic variation
10. Chemical band-aid prevents heart failure in mice with muscular dystrophy
11. MicroRNA tweaks protein that controls early heart development
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/20/2016)...   MedNet Solutions , an innovative SaaS-based eClinical ... research, is pleased to announce the attainment of record-setting ... result of the company,s laser focus on (and growing ... it,s comprehensive, easy-to-use and highly affordable cloud-based technology platform. ... MedNet growth achievements in 2015 include: , ...
(Date:1/15/2016)... JUAN, Puerto Rico , Jan. 15, 2016 /PRNewswire/ ... companies big and small to find new ways to ... driven culture. iOS and Android ... device based on biometrics, transforming it into a hardware ... request that users swipe their fingerprint on their KodeKey ...
(Date:1/11/2016)... , Jan. 11, 2016 Synaptics Incorporated ... interface solutions, today announced that its ClearPad ® ... (TDDI) products won two separate categories in the 8 ... Innovator and Best Technology Breakthrough. The Synaptics ® ... a simplified supply chain, thinner devices, brighter displays and ...
Breaking Biology News(10 mins):
(Date:2/9/2016)... ... February 08, 2016 , ... ... services, announced today the launch of its revamped and improved website. In an ... service solutions, the redesigned website will better communicate how the company designs and ...
(Date:2/9/2016)... ... February 09, 2016 , ... The publishing industry has ... publishing is one of the popular publication models that has received wider acknowledgement ... and 3000+ International Conferences across the globe, OMICS International is all ...
(Date:2/9/2016)... LONDON , February 9, 2016 ... replace paper and protect IP   E-WorkBook ... will be rolled out in Germany ... and protect valuable IP. Users will be able to search ... or experiment as part of the application, to boost collaboration ...
(Date:2/8/2016)... , Feb. 8, 2016 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ... top ten finalists for clean technology companies in the TSX ... top 10 companies listed on the TSX Venture Exchange, in ... gas, clean technology & life sciences, diversified industries ... weighting given to return on investment, market cap growth, trading ...
Breaking Biology Technology: